NYSE
14.27USD
+0.58 (+4.28%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.2B
P/E
—
EPS
—
Beta
3.16
52W range
7.48-18.566
Day range
13.92–14.86
Open
13.96
Prev close
13.68
Volume
2.4M
Avg volume
2.6M
Dividend
0.00
IPO
2022-09-23
https://www.fool.com/coverage/filings/2026/03/21/this-usd8-9-million-buy-targets-a-stock-down-68-with-usd322-million-in-cash/ · 3/21/2026+0.60
https://www.benzinga.com/news/health-care/26/03/51133485/whats-going-on-with-biohaven-stock-on-monday · 3/9/2026+0.40
https://www.fool.com/coverage/filings/2026/03/03/nuvation-bio-stock-up-130-this-past-year-as-one-fund-discloses-usd3-million-buy/ · 3/3/2026+0.10
https://www.zacks.com/stock/news/2847079/is-biohaven-ltd-bhvn-stock-outpacing-its-medical-peers-this-year?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_1-2847079 · 2/10/2026+0.80
https://www.schaeffersresearch.com/content/news/2025/12/26/biohaven-stock-gaps-lower-on-failed-phase-2-drug-trial · 12/26/2025-0.80
https://www.reuters.com/business/healthcare-pharmaceuticals/biohavens-depression-drug-fails-mid-stage-trial-shares-fall-2025-12-24/ · 12/24/2025-0.80
https://www.prnewswire.com/news-releases/fda-issues-complete-response-letter-for-biohavens-vyglxia-troriluzole-new-drug-application-for-spinocerebellar-ataxia-302604884.html · 11/5/2025-1.00
https://www.globenewswire.com/news-release/2025/09/10/3148172/0/en/The-Gross-Law-Firm-Reminds-Shareholders-of-a-Lead-Plaintiff-Deadline-of-September-12-2025-in-Biohaven-Ltd-Lawsuit-BHVN.html · 9/10/2025-1.00
https://www.globenewswire.com/news-release/2025/09/09/3147428/673/en/BHVN-FINAL-DEADLINE-ROSEN-A-TOP-RANKED-LAW-FIRM-Encourages-Biohaven-Ltd-Investors-to-Secure-Counsel-Before-Important-September-12-Deadline-in-Securities-Class-Action-BHVN.html · 9/9/2025-1.00
https://www.prnewswire.com/news-releases/bhvn-deadline-bhvn-investors-have-opportunity-to-lead-biohaven-ltd-securities-fraud-lawsuit-302548099.html · 9/7/2025-1.00
https://www.prnewswire.com/news-releases/investor-deadline-approaching-faruqi--faruqi-llp-investigates-claims-on-behalf-of-investors-of-biohaven-302547285.html · 9/6/2025-1.00
https://www.globenewswire.com/news-release/2025/08/31/3141940/673/en/BHVN-FINAL-DEADLINE-ROSEN-TOP-RANKED-GLOBAL-COUNSEL-Encourages-Biohaven-Ltd-Investors-with-Losses-in-Excess-of-100K-to-Secure-Counsel-Before-Important-September-12-Deadline-in-Secu.html · 8/31/2025-1.00
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
